News Wire
AAP Clinical Report Highlights Early Introduction of Peanut-Based Foods to Prevent Allergies
The American Academy of Pediatrics updates a clinical report that explores how maternal and infant nutrition affect development of infant allergies.
US FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition.
State Legislation Would Provide Epinephrine Auto-Injectors at No Cost to Patients
Bill named 'An Act To Save Lives through Epinephrine Autoinjector Accessibility'.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
Patent Granted for Toothpaste Immunotherapy for Food Allergy
The patent includes claims to the approach of combining allergenic proteins with toothpaste.
AllergyEats Announces 2019 List of Top 10 Most Allergy-Friendly Restaurant Chains in America
Regionally diverse list illustrates growing trend to better accommodate food-allergic diners nationwide.
Egg OIT Leads to More Rapid Allergy Desensitization Than Baked-Egg Products
Study suggests oral immunotherapy may lead to higher sustained unresponsiveness to egg for baked-egg tolerant children.
Study: Allergic Reactions Frequent in Children Undergoing Milk OIT
Allergic reactions frequently occur during treatment and a significant proportion can be classified as anaphylactic, according to a new Canadian study.
Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental Exposures to Peanut...
AR101-Treated Patients Who Completed PALISADE Had 95% Increased Probability of Tolerating Any Dose of Peanut Protein in Exit Challenge Compared to Placebo.
Boiled Peanut OIT Continues to Show Promise as a Safe and Effective Allergy Treatment
Research from a UK clinical trial finds a new oral immunotherapy option provides sustained unresponsiveness one year after treatment.
